Compare GSM & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSM | GERN |
|---|---|---|
| Founded | 2015 | 1990 |
| Country | United Kingdom | United States |
| Employees | N/A | 258 |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 730.6M | 808.3M |
| IPO Year | 2015 | N/A |
| Metric | GSM | GERN |
|---|---|---|
| Price | $3.29 | $1.27 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $6.00 | $2.17 |
| AVG Volume (30 Days) | 1.5M | ★ 14.8M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.36 | $26.91 |
| Revenue Next Year | $17.85 | $43.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.10 | $1.04 |
| 52 Week High | $5.74 | $2.01 |
| Indicator | GSM | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 32.69 | 47.95 |
| Support Level | N/A | $1.23 |
| Resistance Level | $4.68 | $1.30 |
| Average True Range (ATR) | 0.19 | 0.08 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 16.27 | 47.44 |
Ferroglobe PLC provides silicon-based alloys and specialty metals. It produces silicon metal and silicon and manganese-based alloy, serving customers in the specialty chemical, aluminum, solar, steel, and ductile iron foundry industries. The company's operating segments include Canada - Silicon Metals, Canada - Silicon Alloys, U.S. - Silicon Metals, U.S. - Silicon Alloys, Europe - Manganese Alloys, Europe - Silicon Metals, Europe - Silicon Alloys, South Africa - Silicon Metals, South Africa - Silicon Alloys, and Other segments. The primary raw materials the company uses to produce its electrometallurgy products include its coal and quartz mining operations and its silicon metal and ferroalloy production. The firm generates key revenue from Silicon metal and Manganese-based alloys.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.